According to the Zhitong Finance app, AbbVie recently announced a $250 million acquisition of Celsius Therapeutics. Celsius Therapeutics is a clinical-stage biotechnology company focused on developing novel drugs for the treatment of inflammatory diseases. The company's lead candidate drug, CEL383, is a potential first-in-class TREM1-targeted antibody for the treatment of inflammatory bowel disease (IBD).

Celsius Therapeutics' R&D model is to conduct single-cell RNA sequencing on patients' tissues, and then use machine learning and AI to analyze the resulting massive data to identify the factors driving the disease. The occurrence of many diseases may be due to the interaction or joint functional impairment between different types of cells, and traditional gene sequencing may not be able to detect these changes that cause the disease because it detects the average value of multiple cells. Using single-cell RNA sequencing, Celsius can obtain information on gene expression and behavioral changes of cells with very high resolution. These combined with machine learning may provide insights into new targets.